Compare SILC & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SILC | CGEN |
|---|---|---|
| Founded | 1987 | 1993 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 259.1M | 191.1M |
| IPO Year | 2002 | 2001 |
| Metric | SILC | CGEN |
|---|---|---|
| Price | $42.59 | $2.28 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 158.9K | ★ 311.3K |
| Earning Date | 04-30-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.17 | N/A |
| Revenue Next Year | $12.28 | $75.09 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.34 | $1.30 |
| 52 Week High | $52.95 | $3.24 |
| Indicator | SILC | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 49.39 | 54.27 |
| Support Level | $38.07 | $1.48 |
| Resistance Level | $50.42 | $2.35 |
| Average True Range (ATR) | 4.68 | 0.09 |
| MACD | -0.28 | 0.05 |
| Stochastic Oscillator | 34.64 | 95.52 |
Silicom Ltd is engaged in designing, manufacturing, marketing, and supporting high-performance networking and data infrastructure solutions for a broad range of servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, Switches, Edge AI Solutions, Edge Networking Accessories, 4G 5G Products, FPGA-Based Cards, and Others. Its geographic areas are the USA, North America - other, Israel, Europe, and Asia-Pacific. It derives a majority of its revenue from the USA.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.